RESULTS	However , by subgroup analysis , virological response rates were not significantly different between the two therapies in HBeAg-positive patients ( 44.9 % vs. 35.7 % , P = 0.268 ) or in patients with high baseline HBV DNA ( 7 log IU/ml ) ( 40.7 % vs. 31.3 % , P = 0.320 ) at month 24 .\